Abstract
This study surveyed researchers to assess the contents and funding success of federal grant applications for research into therapeutic applications of psychedelics in the United States. The author emailed an anonymous survey to the corresponding authors of the 50 most-cited articles on psychedelics published after 2000 and disseminated it via Twitter. Ten researchers responded, reporting on 24 grant submissions for psilocybin, ibogaine, LSD, MDMA, and other psychedelics, all to the National Institutes of Health (NIH), from the early 1990s onward. The number of grant applications rose noticeably starting in 2006. Of all grant applications assessed,16.7% were funded, lower than the NIH’s 23.4% average funding rate for R-01 equivalent grants between 1998-2023. More specifically, while no relevant grant applications submitted prior to 2006-2010 were funded by NIH, the funding rate of applications since then, estimated at 19.05% to 22.2%, is close to the average annual NIH funding rate of 20.6 ± 1.9% for R-01 equivalent grant applications from 2006 to early 2023. Respondents generally believed applications for this line of research had a lower chance of success compared to other lines of research, although they felt the funding landscape has improved in recent years, in line with this study’s other findings.
Competing Interest Statement
Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics, Compass Pathways, and Livanova. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Cerebral and Janssen Pharmaceuticals for consulting services. Dr. Barnett receives research support from Compass Pathways and MindMed.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Cleveland Clinic waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author contribution statement: Brian Barnett: Conceptualization, Methodology, Writing-original draft preparation
Author disclosure statement: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics, Compass Pathways, and Livanova. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Cerebral and Janssen Pharmaceuticals for consulting services. Dr. Barnett receives research support from Compass Pathways and MindMed.
Funding: This work was unfunded.
Additional analysis has been undertaken, specifically to calculate NIH funding rates for the grant proposals in the sample for 2006-2010 to early 2023 and compare this to publicly available NIH funding rates for R-01 grant applications. The resulting changes and findings were then incorporated into the abstract and body of the paper. A separate table detailing years that grant applications were submitted was also added.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
